Cognition Therapeutics, Inc. Board of Directors

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Ms. Lisa Ricciardi

Ms. Lisa Ricciardi

CEO, President & Director

Mr. Bobby Horn

Mr. Bobby Horn

Corporate Controller

Dr. Anthony O. Caggiano M.D., Ph.D.

Dr. Anthony O. Caggiano M.D., Ph.D.

Chief Medical Officer and Head of R&D

Mr. John Brendan Doyle

Mr. John Brendan Doyle

Chief Financial Officer

Comments